1-20 of 38
Carlos Arteaga
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO3-23-09: ESR1 mutations drive resistance to CDK4/6 inhibitors in ER+ Breast Cancer

M Rosario Chica-Parrado, Chang-Ching Lin, Ellen Jaeger, Michelle Harris, Lei Guo, Emmanuel Bikorimana, Fabiana Napolitano, Calvin Chao, Ariella Hanker, Carlos Arteaga
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-23-09.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-23-09
Published: 02 May 2024
View article titled, Abstract PO3-23-09: ESR1 mutations drive resistance to CDK4/6 inhibitors in ER+ Breast Cancer
Journal Articles

Abstract PO5-15-05: Clinical and genomic landscape of ERBB2 and ERBB3 mutated breast cancer

Nadeem Bilani, Jacqueline Tao, Anton Safonov, Dana Casey, Joshua Drago, Mehnaj Ahmed, Barbara Acevedo, Komal Jhaveri, Jorge Reis-Filho, Mark Robson, Eneda Toska, Ariella Hanker, Carlos Arteaga, Sarat Chandarlapaty, Hanna Y Wen, Pedram Razavi
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO5-15-05.
https://doi.org/10.1158/1538-7445.SABCS23-PO5-15-05
Published: 02 May 2024
View article titled, Abstract PO5-15-05: Clinical and genomic landscape of ERBB2 and ERBB3 mutated breast cancer
Journal Articles

Abstract PO1-23-09: A bedside-to-bench translational analysis demonstrates that NF1 alterations promote CDK4/6 inhibitor (CDK4/6i) resistance in hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Maxwell Lloyd, M Rosario Chica-Parrado, Todd Knepper, Chang-Ching Lin, Emily Podany, Christine Walko, Fabiana Napolitano, Caroline Weipert, Jiemin Liao, Arielle Medford, Lianne Ryan, Jennifer Keenan, Nicole Zhang, Shiyuan Liu, Gerburg Wulf, Katherine Clifton, Cynthia Ma, Hyo Han, Leif Ellisen, Aditya Bardia, Carlos Arteaga, Ariella Hanker, Seth Wander
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO1-23-09.
https://doi.org/10.1158/1538-7445.SABCS23-PO1-23-09
Published: 02 May 2024
View article titled, Abstract PO1-23-09: A bedside-to-bench translational analysis demonstrates that NF1 alterations promote CDK4/6 inhibitor (CDK4/6i) resistance in hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Journal Articles

Abstract PS06-01: Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer

Sherene Loi, Stephen Johnston, Carlos Arteaga, Stephanie Graff, Sarat Chandarlapaty, Matthew Goetz, Christine Desmedt, Jorge Reis-Filho, Hironobu Sasano, Vanessa Rodrik-Outmezguine, Anthony Sireci, Cynthia Sandoval Rubenstein, Helen Won, Deli Liu, Lacey M. Litchfield, Nicholas Turner
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS06-01.
https://doi.org/10.1158/1538-7445.SABCS23-PS06-01
Published: 02 May 2024
View article titled, Abstract PS06-01: Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer
Journal Articles

Abstract PS17-09: An FGFR1/2 degrader overcomes antiestrogen resistance in ER+/FGFR1-amplified breast cancer

Yasuaki Uemoto, Chang-Ching Lin, Alberto Servetto, Bingnan Wang, Dan Ye, Fabiana Napolitano, Hima Milan Patel, Luigi Formisano, M Rosario Chica-Parrado, Emmanuel Bikorimana, Saurabh Mendiratta, Chuo Chen, Ariella Hanker, Carlos Arteaga
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS17-09.
https://doi.org/10.1158/1538-7445.SABCS23-PS17-09
Published: 02 May 2024
View article titled, Abstract PS17-09: An FGFR1/2 degrader overcomes antiestrogen resistance in ER+/FGFR1-amplified breast cancer
Journal Articles

Abstract PS03-04: Tumor immune microenvironment modulates resistance to estrogen suppression in ER+ breast cancer

Fabiana Napolitano, Yunguan Wang, Dhivya Sudhan, Paula Gonzalez-Ericsson, Luigi Formisano, Lei Guo, M Rosario Chica-Parrado, Chang-Ching Lin, Kyung-Min Lee, Hongli Ma, Nathaniel Evans, Alberto Servetto, Saurabh Mendiratta, Spencer Barnes, Yisheng Fang, Lin Xu, Justin Balko, Gordon Mills, Marilyne Labrie, Ariella Hanker, Carlos Arteaga
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS03-04.
https://doi.org/10.1158/1538-7445.SABCS23-PS03-04
Published: 02 May 2024
View article titled, Abstract PS03-04: Tumor immune microenvironment modulates resistance to estrogen suppression in ER+ breast cancer
Journal Articles

Abstract PO1-19-08: Phase I trial of pegylated liposomal doxorubicin chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer

Sangeetha Reddy, Joyce O'Shaughnessy, Navid Sadeghi, Samira Syed, Cesar Santa-Maria, Virginia Kaklamani, Nan Chen, Denise Yardley, Yisheng Fang, Isaac Chan, Nisha Unni, Sarah Kashanian, Namrata Peswani, Shahbano Shakeel, Meredith Carter, Kelly Kyle, Farjana Fattah, Chul Ahn, Ina Patel, Joshua Gruber, Dawn Klemow, Glenda Delgado, Nicole Sinclair, Michael Yellin, Heather McArthur, Rita Nanda, Suzanne Conzen, Carlos Arteaga
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO1-19-08.
https://doi.org/10.1158/1538-7445.SABCS23-PO1-19-08
Published: 02 May 2024
View article titled, Abstract PO1-19-08: Phase I trial of pegylated liposomal doxorubicin chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer
Journal Articles

Abstract GS03-06: Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial

Nicholas Turner, Jorge Reis-Filho, Matthew Goetz, Christine Desmedt, Sarat Chandarlapaty, Hironobu Sasano, Carlos Arteaga, Sherene Loi, Stephanie Graff, Deli Liu, Vanessa Rodrik-Outmezguine, Anthony Sireci, Cynthia Sandoval Rubenstein, Helen Won, Lacey M. Litchfield, Maria Munoz, Stephen Johnston
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): GS03-06.
https://doi.org/10.1158/1538-7445.SABCS23-GS03-06
Published: 02 May 2024
View article titled, Abstract GS03-06: Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
Journal Articles

Abstract P2-20-01: Patient-derived triple-negative breast cancer organoids as a platform for glucocorticoid receptor- mediated mechanisms of immunotherapy response and resistance

Christine Shiang, Candace Frerich, Ishrat Durdana, Cheryl Lewis, Lynda B. Bennett, Carlos Arteaga, Suzanne D. Conzen
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P2-20-01.
https://doi.org/10.1158/1538-7445.SABCS22-P2-20-01
Published: 01 March 2023
View article titled, Abstract P2-20-01: Patient-derived triple-negative breast cancer organoids as a platform for glucocorticoid receptor- mediated mechanisms of immunotherapy response and resistance
Journal Articles

Abstract PD17-08: Pooled gene expression analysis and association with treatment response in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 trials

Aditya Bardia, Faye Su, Nadia Solovieff, Fabrice Andre, Carlos Arteaga, Patrick Neven, Yoon-Sim Yap, Yen-Shen Lu, Stephen K. Chia, Dennis Slamon, Seock-Ah Im, Arunava Chakravartty, Agnes Lteif, Tetiana Taran, Debu Tripathy
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD17-08.
https://doi.org/10.1158/1538-7445.SABCS22-PD17-08
Published: 01 March 2023
View article titled, Abstract PD17-08: Pooled gene expression analysis and association with treatment response in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 trials
Journal Articles

Abstract OT2-17-01: Phase 1 trial of anthracycline chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer

Sangeetha Reddy, Meredith Carter, Isaac Chan, Nisha Unni, Namrata Peswani, Dawn Klemow, Samira Syed, Shahbano Shakeel, Farjana Fattah, Chul Ahn, Yisheng Fang, Heather McArthur, Nicole Sinclair, Michael Yellin, Denise Yardley, Nan Chen, Joyce O’Shaughnessy, Rita Nanda, Suzanne D. Conzen, Carlos Arteaga
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT2-17-01.
https://doi.org/10.1158/1538-7445.SABCS22-OT2-17-01
Published: 01 March 2023
View article titled, Abstract OT2-17-01: Phase 1 trial of anthracycline chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer
Journal Articles

Abstract P5-02-02: Genomic Landscape of ER+/HER2- metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor

M Rosario Chica-Parrado, Chang-Ching Lin, Timothy Mahoney, Elizabeth Mauer, Ariella Hanker, Carlos Arteaga
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P5-02-02.
https://doi.org/10.1158/1538-7445.SABCS22-P5-02-02
Published: 01 March 2023
View article titled, Abstract P5-02-02: Genomic Landscape of ER+/HER2- metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor
Journal Articles

Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials

Fabrice Andre, Nadia Solovieff, Faye Su, Aditya Bardia, Patrick Neven, Yoon-Sim Yap, Debu Tripathy, Yen-Shen Lu, Dennis Slamon, Stephen K. Chia, Mukta Joshi, Arunava Chakravartty, Agnes Lteif, Tetiana Taran, Carlos Arteaga
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P5-02-14.
https://doi.org/10.1158/1538-7445.SABCS22-P5-02-14
Published: 01 March 2023
View article titled, Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
Journal Articles

Abstract PL2: Plenary Lecture 2: Premenopausal ER+ Breast Cancer: Past, Present, and Future

Carlos Arteaga, Prudence Francis
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PL2.
https://doi.org/10.1158/1538-7445.SABCS22-PL2
Published: 01 March 2023
View article titled, Abstract PL2: Plenary Lecture 2: Premenopausal ER+ Breast Cancer: Past, Present, and Future
Journal Articles

Abstract PD3-07: Combined inhibition of CDK4/6 and AKT is effective in Rb-intact triple-negative breast cancer of the luminal androgen receptor (LAR) subtype

Gun Min Kim, Kyung-min Lee, Dhivya Sudhan, Albert Lin, Arnaldo Marin, Sumanta Chatterjee, Dan Ye, Vishal Kandagatla, Saurabh Mendiratta, Ariella Hanker, Carlos Arteaga
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD3-07.
https://doi.org/10.1158/1538-7445.SABCS21-PD3-07
Published: 15 February 2022
View article titled, Abstract PD3-07: Combined inhibition of CDK4/6 and AKT is effective in Rb-intact triple-negative breast cancer of the luminal androgen receptor (LAR) subtype
Journal Articles

Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2− breast cancer

Joyce O'Shaughnessy, Salomon M Stemmer, Howard A Burris, Yoon-Sim Yap, Gabe Sonke, Lowell Hart, Mario Campone, Katarina Petrakova, Eric P Winer, Wolfgang Janni, Pierfranco Conte, David A Cameron, Fabrice André, Carlos Arteaga, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Gabriel N Hortobagyi
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS2-01.
https://doi.org/10.1158/1538-7445.SABCS21-GS2-01
Published: 15 February 2022
View article titled, Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2− breast cancer
Journal Articles

Abstract CT061: Binimetinib in patients with tumors with NRAS mutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A

James M. Cleary, Victoria Wang, Rebecca Heist, Scott Kopetz, Edith P. Mitchell, James Zwiebel, Helen X. Chen, Shuli Li, Robert Gray, Lisa McShane, Larry Rubinstein, David Patton, Funda Meric-Bernstam, Melissa Dillmon, Mickey Williams, Stanley Hamilton, Barbara Conley, Peter O'Dwyer, Lyndsay Harris, Carlos Arteaga, Alice Chen, Keith Flaherty
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT061.
https://doi.org/10.1158/1538-7445.AM2020-CT061
Published: 15 August 2020
View article titled, Abstract CT061: Binimetinib in patients with tumors with <em>NRAS</em> mutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A
Journal Articles

Abstract GS6-06: A neoadjuvant trial with letrozole identifies PRR11 in the 17q23 amplicon as a mechanism of resistance to endocrine therapy in ER-positive breast cancer

Kyung-min Lee, Angel Guerrero-Zotano, Ariella Hanker, Alberto Servetto, Dhivya Sudhan, Luigi Formisano, Valerie Jansen, Paula González-Ericsson, Melinda Sanders, Thomas Stricker, Lewis Cantley, Carlos Arteaga
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): GS6-06.
https://doi.org/10.1158/1538-7445.SABCS19-GS6-06
Published: 15 February 2020
View article titled, Abstract GS6-06: A neoadjuvant trial with letrozole identifies <em>PRR11</em> in the 17q23 amplicon as a mechanism of resistance to endocrine therapy in ER-positive breast cancer
Journal Articles

Abstract OT1-07-05: TROPiCS-02: phase 3 study of Sacituzumab Govitecan (IMMU-132) in relapsed/refractory hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC)

Hope S Rugo, Aditya Bardia, Sara M. Tolaney, Carlos Arteaga, Javier Cortes, Joohyuk Sohn, Frederik Marmé, Quan Hong, Scott Hofsess, Martin Olivo, André Fabrice, Peter Schmid
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): OT1-07-05.
https://doi.org/10.1158/1538-7445.SABCS19-OT1-07-05
Published: 15 February 2020
View article titled, Abstract OT1-07-05: TROPiCS-02: phase 3 study of Sacituzumab Govitecan (IMMU-132) in relapsed/refractory hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC)
Journal Articles

Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial

Helen H. Won, S. Duygu Selcuklu, Sarina A. Piha-Paul, Cristina Saura, Jordi Rodon, Ingrid A. Mayer, Sherene Loi, Geoffrey I. Shapiro, Janice Lu, Adam Brufsky, Catherine Zimel, Myra Melcer, Maurizio Scaltriti, Lisa D. Eli, Richard E. Cutler, Jr., Alshad S. Lalani, Richard P. Bryce, Carlos Arteaga, Funda Meric-Bernstam, Michael F. Berger, David B. Solit, Alison Schram, David M. Hyman
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 929.
https://doi.org/10.1158/1538-7445.AM2019-929
Published: 01 July 2019
View article titled, Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial